Advertisement

Topics

AbbVie’s Mavyret secures FDA approval for chronic hepatitis C treatment

05:02 EDT 7 Aug 2017 | Pharmaceutical Business Review

The US Food and Drug Administration (FDA) has approved AbbVie's Mavyret (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment has been approved by for treating adult patients with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6).

Original Article: AbbVie’s Mavyret secures FDA approval for chronic hepatitis C treatment

NEXT ARTICLE

More From BioPortfolio on "AbbVie’s Mavyret secures FDA approval for chronic hepatitis C treatment"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...